Fig. 4
From: 4D label-free proteomics analysis of oxygen-induced retinopathy with or without anti-VEGF treatment
GO annotation and GO enrichment analyses of the DEPs. A GO enrichment analysis of the DEPs (Top 20) between the ranibizumab group and the OIR group. B GO enrichment analysis of the DEPs (Top 20) between the OIR group and the normal group. C GO enrichment analysis of the DEPs (Top 20) between the ranibizumab group and the normal group. D GO annotation analysis of the DEPs (Top 10) of the three groups